TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia

Irene M. Ghobrial, David S. Siegel, Ravi Vij, Jesus G. Berdeja, Paul G. Richardson, Rachel Neuwirth, Chirag G. Patel, Fabian Zohren, Jeffrey L. Wolf

Research output: Contribution to journalArticlepeer-review

71 Scopus citations

Fingerprint

Dive into the research topics of 'TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia'. Together they form a unique fingerprint.

Medicine & Life Sciences